نبذة مختصرة : Introduction: breast cancer is the most frequent pathology within carcinomas occurring in females. It happens when breast cells grow uncontrolled due to failure of proliferative regulatory mechanisms. Current treatments involve high adverse effects for the health of patients and the efficacy in many cases is not as expected.Objective: to describe the advances in the treatment of breast carcinoma which are based on high biological activity, selectivity and low toxicity.Methods: articles related to the research were taken from SciELO, Pubmed, Springer, ScienceDirect, Mediagraphic and Redalyc databases. Theoretical methods of analysis and synthesis allowed the study of the topic in question, and 75 % of the publications of the last three years were chosen.Development: work is currently underway on the development of new drugs against breast cancer including STAT3 transcription factor inhibitors, PARP poly-ADP-ribose polymerase (PARP) inhibitors and the use of micro-RNA biomarkers. Molecular docking techniques have allowed the design of estrogen receptor and human epidermal growth factor inhibitors with lower energy values than natural compounds.Conclusions: the development of potential candidates aims at decreasing tumor toxicity and invasiveness as well as increasing selectivity and biological activity. The design of master keys may be an attractive option against breast cancer. ; Introducción: el cáncer de seno es la patología más frecuente dentro de los carcinomas que ocurren en las féminas. Sucede cuando las células mamarias crecen de forma descontrolada debido al fallo de los mecanismos regulatorios proliferativos. Los tratamientos actuales suponen elevados efectos adversos para la salud de los pacientes y la eficacia en muchos casos, no es la esperada.Objetivo: describir los avances en el tratamiento del carcinoma mamario que se basan en una alta actividad biológica, selectividad y baja toxicidad.Métodos: a partir de la consulta de las bases de datos Scielo, Pubmed, Springer, Science Direct, Mediagraphic y ...
Relation: https://revcmpinar.sld.cu/index.php/publicaciones/article/view/5195/pdf; https://revcmpinar.sld.cu/index.php/publicaciones/article/view/5195/4905; Ramírez Valle M, García Montesino G. Cáncer de mama invasivo según subtipos moleculares en la provincia de Pinar del Río. Rev Ciencias Médicas. [Internet]. 2020 [citado 2021/05/16]; 24(5): e4362. Disponible en: http://revcmpinar.sld.cu/index.php/publicaciones/article/view/4362; Ramírez Valle M, García Montesino G, Lores Hechevarria C, Sánchez Azcuy Y, Márquez Hernández C. Histological and immunohistochemistry of invasive breast cancer in Pinar del Río province Cuba. Rev Ciencias Médicas. [Internet]. 2019 [citado 2021/03/01]; 23(1): 71-78. Disponible en: http://revcmpinar.sld.cu/index.php/publicaciones/article/view/3801; Valdés Lara G, García Espinosa A, Pedroso Morales I. La rehabilitación del cáncer de mama en Cuba. Rev Invest. Medicoquir [Internet]. 2019 [citado 2021/05/13]; 11(supl.1): [aprox. 18 pp.]. Disponible en: https://www.medigraphic.com/pdfs/invmed/cmq-2019/cmqs191v.pdf; Ministerio de Salud Pública. Dirección de Registros Médicos y Estadísticas de Salud. Anuario estadístico 2018. La Habana: MINSAP[Internet]; 2019. Disponible en: https://files.sld.cu/bvscuba/files/2019/04/Anuario-Electr%C3%B3nico-Espa%C3%B1ol-2018-ed-2019-compressed.pdf; Peña García Y, Maceo González M, Ávila Céspedes D, Utria Velázquez L, Más López Y. Factores de riesgo para padecer cáncer de mama en la población femenina. Rev Finlay [Internet]. 2017 [citado 2021/02/25]; 7(4): 283-289. Disponible en: http://scielo.sld.cu/pdf/rf/v7n4/rf08407.pdf; Echevarría Lores C. El carcinoma de mama. Caracterización clínico-patológica en un hospital de la atención secundaria pinareña. Rev Ciencias Médicas [Internet]. 2016 [citado 2021/05/13]; 20(1): 75-79. Disponible en: http://www.revcmpinar.sld.cu/index.php/publicaciones/article/view/2542; Raya Pérez JC. Las bases moleculares del cáncer. Acta Universitaria [Internet]. 2006 [citado 2021/02/28]; 16(1): 40-49. Disponible en: https://www.redalyc.org/pdf/416/41616105.pdf; Hernández DE. Biología del cáncer de mama. Rev Venez Oncol [Internet]. 2016 [citado 2021/03/02]; 28(3): 188-200. Disponible en: https://www.redalyc.org/pdf/3756/375645930010.pdf; Sherr CJ. Principles of tumor suppression. Rev Cell [Internet]. 2004 [citado 2021/03/02]; 116(2): 235-246. Disponible en: https://www.sciencedirect.com/science/article/pii/S0092867403010754; Isakoff SJ. Triple Negative Breast Cancer: Role of Specific Chemotherapy Agents. Cancer J [Internet]. 2010 [citado 2021/03/2]; 16(1): 53–61. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882502/; Waks A, Winer E. Breast Cancer Treatment. A Review. JAMA [Internet]. 2019 [citado 2021/02/28]; 321(3): 288-300. Disponible en: https://jamanetwork.com/journals/jama/article-abstract/2721183; Joshi Himanshu MF. Press. Molecular oncology of breast cancer. The Breast [Internet]. 2018 [citado 2021/02/28]; (22): 282-307. Disponible en: https://www.sciencedirect.com/science/article/pii/B9780323359559000222; Yuan J, Xiao C, Lu H, Yu H, Hong H, Guo C et al. Effects of various treatment approaches for treatment efficacy for late stage breast cancer and expression level of TIMP-1 and MMP-9. Cancer Biomarkers [Internet]. 2018 [citado 2021/02/25]; 23(1): 1–7. Disponible en: https://content.iospress.com/articles/cancer-biomarkers/cbm170901; Smith J, Buyse M, Rastogi P, Geyer C, Jacobs S, Patocskai E, et al. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5. Clin Breast Cancer [Internet]. 2017 [citado 2021/02/28]; 17(1): 48-54. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1526820916302014; Halil Yildirim I, Ahmed Azzawri A, Duran T. Thymoquinone induces apoptosis via targeting the Bax/BAD and Bcl-2 pathway in breast cancer cells. Dicle Tip Dergisi/Dicle Med [Internet]. 2019 [citado 2021/02/25]; 46(3): 411–417. Disponible en: https://dergipark.org.tr/en/download/article-file/808246; Qin J, Yan L, Zhang J, Zhang W. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. Journal of Experimental and Clinical Cancer Research [Internet]. 2019 [citado 2021/02/28]; 38(195): 1-16. Disponible en: https://link.springer.com/article/10.1186/s13046-019-1206-z; Adhami M, Akbar Haghdoost A, Malekpour Afshar R. Candidate miRNA in human breast cancer biomarkers: a systematic review. Breast Cancer [Internet]. 2018 [citado 2021/03/02]; 25: 198-205. Disponible en: https://link.springer.com/article/10.1007/s12282-017-0814-8; Papadimitriou M, Mountzios G, Papadimitrioua C. The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum on syntetic lethality. Cancer treatment reviews [Internet]. 2018 [citado 2021/03/02]; 67: 37-44. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0305737218300549; Márquez Fernández ME, Camargo M. Therapeutic potential of omega fatty acids in breast cancer. Vitae [Internet]. 2019 [citado 2021/02/26]; 2(1): 23-43. Disponible en: http://www.scielo.org.co/scielo.php?pid=S0121-40042019000100023&script=sci_arttext&tlng=en; De Cicco P, Catani MV, Gasperi V, Sibilano M, Quaglietta M, Savini I. Nutrition and Breast Cancer: A Literature Review on Prevention, Treatment and Recurrence. Nutrients [Internet]. 2019 [citado 2021/02/28]; 11(7): 1514. Disponible en: https://www.mdpi.com/2072-6643/11/7/1514; León Barrios Y, Céspedes Quevedo M, Vinent Céspedes A. Neutropenia inducida por citostáticos en oncología. Medisan [Internet]. 2017 [citado 2021/03/01]; 21(11): 3163-3171. Disponible en: https://www.medigraphic.com/pdfs/medisan/mds-2017/mds1711d.pdf; Soriano García J, Batista Albuerne N, Lima Pérez M, González González J, Gutiérrez Rojas A, Luaces Álvarez P. Evaluación del uso de ácido zoledrónico en pacientes con cáncer de mama metastásico a hueso. Rev Cubana de Medicina [Internet]. 2010 [citado 2021/03/01]; 49(1): 33-64. Disponible en: http://scielo.sld.cu/pdf/med/v49n1/med04110.pdf; Portelles Cruz A, Rodríguez Alberteris Y, Fernández Sarabia P, Sanz Pupo N, Oller Pousada J. Quimioterapia neoadyuvante en cáncer de mama, localmente avanzado. Rev CCM [Internet]. 2013 [citado 2021/03/01]; 17(4): 433-442. Disponible en: http://scielo.sld.cu/pdf/ccm/v17n4/ccm03413.pdf; Soriano García J, Lima Pérez M, Batista Albuerne N, González González J, Manuel Pangui S. Evaluación del uso del esquema de paclitaxel con carboplatino en pacientes con cáncer de mama metastásico. Revista Cubana de Medicina [Internet]. 2009 [citado 2021/03/02]; 48(2): 1-15. Disponible en: http://scielo.sld.cu/pdf/med/v48n2/med03209.pdf; Parvizpour S, Razmara J, Pourseif M, Omidi Y. In silico design of a triple-negative breast cancer vaccine by targeting cancer testis antigens. BioImpacts [Internet]. 2019 [citado 2021/03/02]; 9(1): 45-56. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378095; Speck Planche A, Cordeiro N. Fragment-based in silico modeling of multi-target inhibitors against breast cancer-related proteíns. Molecular Diversity [Internet]. 2017 [citado 2021/03/04]; 21: 511-523. Disponible en: https://link.springer.com/article/10.1007/s11030-017-9731-1; Sinha S, Patel S, Athar M, Vora J, Chhabria MT, Jha PC, Shrivastava N. Structure-based identification of novel sirtuin inhibitors against triple negative breast cancer: An in silico and in vitro study. Rev Int J Biol Macromol [Internet]. 2019 [citado 2021/02/25];140: 454-468. Disponible en: https://www.sciencedirect.com/science/article/pii/S0141813019343594; Suryani Y, Opik T, Siti R, Ida K, Epa P. In silico analysis of formononetin compound as a breast anti cancer. Rev Latinoamérica de Hipertensión [Internet]. 2018 [citado 2021/02/26]; 13(6): 579-583. Disponible en: http://digilib.uinsgd.ac.id/id/eprint/31047; https://revcmpinar.sld.cu/index.php/publicaciones/article/view/5195
Processing Request
No Comments.